Can The Pharmaceutical Industry Be Trusted Case Study

PAGES
3
WORDS
988
Cite

Anglo American

5-3. Because such a large percentage of its workforce consists of migrant workers who are more likely to acquire and spread HIV/AIDS, should Anglo adopt the policy of not hiring migrant workers? Should the South African government close the doors to migrant workers?

Anglo should not discriminate against migrant workers just because of the HIV stigma. Stigma is a real thing and can do a great more damage to people than even the so-called disease might do. In Africa, the stigma of HIV is a serious risk that people do not want to accept (Anglo-American Case, n.d.). Therefore, many of them do not want to get tested. If a person does not want to get tested, his wishes and desires should be respected: after all, it is that persons body and a person should have autonomy over his own health and body. It is not Anglos job to test its employees or to provide drugs that people may not even want. By simply changing its strategy from one of attempting to reduce the spread of HIV to one of respecting workers rights and attitudes, Anglo could save hundreds of millions of dollars. Considering all the uncertainties surrounding HIV and all the misinformation too, it appears that Anglo has taken on a corporate social responsibility policy that is more harmful than good. Adopting a policy of discriminating against migrant workers would be like adding fuel to the fire. It would worsen Anglos position and further reduce its profitability.

Additionally, the South African government should not close its doors to migrant workers. Migrant workers come to South Africa for a variety of reasons. Some are fleeing persecution or conflict in their home countries, while others are simply seeking better economic opportunities. Whatever their reasons, it is important to remember that they are human beings with rights. Closing the doors to migrant workers would be a violation of their human rights and would set a dangerous precedent. Additionally, it is worth noting that...…own gain.

Anglo American should be careful to avoid falling into the trap of playing into the wishes of another industry that actually does no good for the people or the business that Anglo is trying to conduct. There may be many other reasons for Africans poor health; one should not just accept the health industrys word as gospel truthand that should be evident to one and all especially after the COVID madness that swept the world in 2020 at the direction of the global health industry and organizations. Anglo would do very well simply to give back to the community, to support agricultural efforts, and to welcome migrant workers. There is no need to support a drug or vaccine program that the people themselves are wary of. The company should respect the rights of the people to make their own choices and it should not pursue a policy of exploitation promoted by the same pharmaceutical industry responsible for the opioid epidemic in America. It simply ought…

Sources Used in Documents:

References

Anglo-American Case. (n.d.). Comparative Environmental Frameworks.

News24. (2012). Aids is not killing African economies. Retrieved from https://www.news24.com/health24/Medical/HIV-AIDS/News/Aids-is-not-killing-African-economies-20120721

Rasool, F., & Botha, C. J. (2011). The nature, extent and effect of skills shortages onskills migration in South Africa. SA Journal of Human Resource Management, 9(1), 1-12.


Cite this Document:

"Can The Pharmaceutical Industry Be Trusted" (2022, October 04) Retrieved April 28, 2024, from
https://www.paperdue.com/essay/pharmaceutical-industry-trusted-case-study-2179040

"Can The Pharmaceutical Industry Be Trusted" 04 October 2022. Web.28 April. 2024. <
https://www.paperdue.com/essay/pharmaceutical-industry-trusted-case-study-2179040>

"Can The Pharmaceutical Industry Be Trusted", 04 October 2022, Accessed.28 April. 2024,
https://www.paperdue.com/essay/pharmaceutical-industry-trusted-case-study-2179040

Related Documents

This relationship has an effect on the payment rates that CMS sets. Higher cost pharmaceutical therapies are systematically reimbursed below acquisition cost (i.e., the payment system is biased against full reimbursement for higher cost therapies). Reimbursement compared to acquisition cost for the top IO pharmaceuticals by total expenditures indicates that 9 of the 10 are significantly under reimbursed." Clinical Trials Report: Congress established Medicare beneficiaries numbering 40 million with a prescription

38 per share on the company's common stock for the first quarter of 2005. The dividend is payable January 3, 2005 to stockholders of records at the close of business on December 3, 2004. Growth in the ZETIA and VYTORIN franchises are expected to continue. T There are currently several candidates in Phase III that Merck plans to file in 2005 as well as Type 2 diabetes treatment and three vaccines.

There are two constant irritations in U.S. pharma companies' relationships internationally: Some developing nations, such as India, Brazil and South Africa, are chipping away at the patent situation, trying to shorten the time until the drugs can be brought out in generic form. The U.S. has supported high prices as the cost for innovation. Since other countries are not playing along, this means that their citizens are benefiting from the innovation paid

For example, before its paten ran out, "the price of Schering-Plough's top-selling allergy pill, Claritin, was raised thirteen times over fives years, for a cumulative increase of more than 50%, over four times the rate of general inflation." In 2002, the average price of the fifty drugs most used by senior citizens was approximately $1,500 for a year's supply, and although this refers to what the companies call the

McKesson Corporation (Mckesson) is an American pharmaceutical distributor with operations mainly in the U.S. The firm has been in operation since 1833, and boasts extensive market share, robust financial strength, and strong market power. The firm has built strong relationships with its key stakeholders, which adds to its strengths. Nonetheless, limited diversification and market focus as well as the threats of competition, unfavourable regulatory changes, and counterfeits present significant concerns

Pharmaceutical Ethics Issues Generally, business ethics is a concept that has not been upheld or exemplified to any high standard by the modern pharmaceutical industry. It is an industry frequently plagued by unethical marketing decisions and practices, the pursuit of business strategies and policies that violate public trust in spirit if not necessarily in the written word, and that has embraced research practices that are sometimes highly questionable. In the modern